Equities

Getein Biotech Inc

603387:SHH

Getein Biotech Inc

Actions
Health CareMedical Equipment and Services
  • Price (CNY)7.20
  • Today's Change-1.74 / -19.46%
  • Shares traded1.36m
  • 1 Year change-37.77%
  • Beta0.7383
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0381,1661,558
Total Receivables, Net501535499
Total Inventory230269252
Prepaid expenses426533
Other current assets, total34136324
Total current assets2,1512,3992,365
Property, plant & equipment, net708562457
Goodwill, net262626
Intangibles, net182141105
Long term investments641492143
Note receivable - long term8.239.2511
Other long term assets------
Total assets3,7723,6793,138
LIABILITIES
Accounts payable129121121
Accrued expenses9011195
Notes payable/short-term debt646569473
Current portion long-term debt/capital leases23312.30
Other current liabilities, total90126122
Total current liabilities978958813
Total long term debt2.717.6530
Total debt672608505
Deferred income tax272414
Minority interest182182168
Other liabilities, total22246.67
Total liabilities1,2121,1961,032
SHAREHOLDERS EQUITY
Common stock507507364
Additional paid-in capital314318512
Retained earnings (accumulated deficit)1,7371,6571,281
Treasury stock - common----(50)
Unrealized gain (loss)------
Other equity, total0.930.570.04
Total equity2,5592,4822,106
Total liabilities & shareholders' equity3,7723,6793,138
Total common shares outstanding507507508
Treasury shares - common primary issue001.37
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.